Search

Your search keyword '"McGahren, Eugene D."' showing total 206 results
Start Over Author "McGahren, Eugene D."
206 results on '"McGahren, Eugene D."'

2. Evaluation of the diagnostic biopsy approach for children with hepatoblastoma: A report from the children’s oncology group AHEP 0731 liver tumor committee

Author

Weldon, Christopher B, Madenci, Arin L, Tiao, Gregory M, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Ranganathan, Sarangarajan, López-Terrada, Dolores H, Finegold, Milton J, Malogolowkin, Marcio H, Piao, Jin, Huang, Li, Krailo, Mark D, Meyers, Rebecka L, and Katzenstein, Howard M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Liver Disease, Rare Diseases, Cancer, Pediatric, Clinical Research, Pediatric Cancer, Pediatric Research Initiative, Adolescent, Biopsy, Child, Child, Preschool, Female, Hepatoblastoma, Humans, Infant, Laparoscopy, Liver Neoplasms, Male, Neoplasm Staging, Postoperative Hemorrhage, Intraoperative complications, Minimally invasive surgical procedures, Pediatrics, Oncology, Paediatrics and Reproductive Medicine, Clinical sciences, Paediatrics
Abstract

BackgroundThe histopathological assessment of pediatric liver tumors at presentation is critical to establish a diagnosis, guide treatment, and collect appropriate research samples. The purpose of this study was to evaluate complications associated with different approaches to liver biopsy for newly diagnosed hepatoblastoma.MethodsChildren with hepatoblastoma were enrolled on Children's Oncology Group study AHEP0731 (September 2009-March 2012). This analysis evaluated the study cohort of initially unresectable patients who therefore underwent a biopsy procedure at diagnosis. The primary endpoint was clinically significant postbiopsy hemorrhage, defined as requiring red blood cell transfusion.ResultsWe identified 121 children who underwent open (n = 76, 63%), laparoscopic (n = 17, 14%), or percutaneous (n = 28, 23%) liver biopsies. All biopsy procedures yielded adequate tissue for diagnosis. Postbiopsy hemorrhage requiring transfusion occurred after 26% (n = 31) of biopsies. Need for blood product transfusion most frequently occurred following open (n = 27/76, 36%) and laparoscopic (n = 4/17, 24%) biopsies, compared with percutaneous (n = 0/28, 0%) biopsies (p

Published
2020

3. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial

Author

Katzenstein, Howard M, Langham, Max R, Malogolowkin, Marcio H, Krailo, Mark D, Towbin, Alexander J, McCarville, Mary Beth, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen, McGahren, Eugene D, Tiao, Gregory M, O'Neill, Allison F, Qayed, Muna, Furman, Wayne L, Xia, Caihong, Rodriguez-Galindo, Carlos, and Meyers, Rebecka L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Pediatric, Clinical Trials and Supportive Activities, Pediatric Cancer, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Child, Child, Preschool, Cisplatin, Disease Progression, Female, Fluorouracil, Hepatectomy, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Male, Neoplasm Staging, Progression-Free Survival, Risk Assessment, Risk Factors, Time Factors, United States, Vincristine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundHepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy.MethodsIn this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children

Published
2019

4. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731

Author

Vasudevan, Sanjeev A, Meyers, Rebecka L, Finegold, Milton J, López-Terrada, Dolores, Ranganathan, Sarangarajan, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Tiao, Greg M, Weldon, Christopher B, Malogolowkin, Marcio H, Krailo, Mark D, Piao, Jin, Randazzo, Jessica, Towbin, Alexander J, BethMcCarville, M., O'Neill, Allison F, Furman, Wayne L, Rodriguez-Galindo, Carlos, and Katzenstein, Howard M

Published
2022
Full Text
View/download PDF

7. Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee

Author

Katzenstein, Howard M, Furman, Wayne L, Malogolowkin, Marcio H, Krailo, Mark D, McCarville, M Beth, Towbin, Alexander J, Tiao, Greg M, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Rodriguez‐Galindo, Carlos, and Meyers, Rebecka L

Subjects
Cancer, Pediatric Cancer, Pediatric, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Child, Child, Preschool, Female, Hepatectomy, Hepatoblastoma, Humans, Infant, Irinotecan, Liver Neoplasms, Liver Transplantation, Male, Survival Rate, Vincristine, alpha-Fetoproteins, hepatoblastoma, high-risk, irinotecan, metastatic, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma.MethodsPatients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level 1 log10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone.ResultsA total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively.ConclusionsThe VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. Cancer 2017;123:2360-2367. © 2017 American Cancer Society.

Published
2017

10. Relationships between Preclinical Course Grades and Standardized Exam Performance

Author

Hu, Yinin, Martindale, James R., LeGallo, Robin D., White, Casey B., McGahren, Eugene D., and Schroen, Anneke T.

Abstract

Success in residency matching is largely contingent upon standardized exam scores. Identifying predictors of standardized exam performance could promote primary intervention and lead to design insights for preclinical courses. We hypothesized that clinically relevant courses with an emphasis on higher-order cognitive understanding are most strongly associated with performance on United States Medical Licensing Examination Step exams and National Board of Medical Examiners clinical subject exams. Academic data from students between 2007 and 2012 were collected. Preclinical course scores and standardized exam scores were used for statistical modeling with multiple linear regression. Preclinical courses were categorized as having either a basic science or a clinical knowledge focus. Medical College Admissions Test scores were included as an additional predictive variable. The study sample comprised 795 graduating medical students. Median score on Step 1 was 234 (interquartile range 219-245.5), and 10.2% (81/795) scored lower than one standard deviation below the national average (205). Pathology course score was the strongest predictor of performance on all clinical subject exams and Step exams, outperforming the Medical College Admissions Test in strength of association. Using Pathology score <75 as a screening metric for Step 1 score <205 results in sensitivity and specificity of 37 and 97%, respectively, and a likelihood ratio of 11.9. Performance in Pathology, a clinically relevant course with case-based learning, is significantly related to subsequent performance on standardized exams. Multiple linear regression is useful for identifying courses that have potential as risk stratifiers.

Published
2016
Full Text
View/download PDF

11. Vincristine/irinotecan/temsirolimus upfront window treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee

Author

Thompson, Patrick A., primary, Malogolowkin, Marcio H., additional, Furman, Wayne L., additional, Piao, Jin, additional, Krailo, Mark D., additional, Chung, Nadia, additional, Brock, Lindsay, additional, Towbin, Alexander J., additional, McCarville, Elizabeth B., additional, Finegold, Milton J., additional, Ranganathan, Sarangarajan, additional, Dunn, Stephen P., additional, Langham, Max R., additional, McGahren, Eugene D., additional, Tiao, Gregory M., additional, Weldon, Christopher B., additional, O'Neill, Allison F., additional, Rodriguez‐Galindo, Carlos, additional, Meyers, Rebecka L., additional, and Katzenstein, Howard M., additional

Published
2023
Full Text
View/download PDF

16. Pediatric Hernias

Author

Rodgers, Bradley M., McGahren, Eugene D., III, Burns, Robert C., Bendavid, Robert, editor, Abrahamson, Jack, editor, Arregui, Maurice E., editor, Flament, Jean Bernard, editor, and Phillips, Edward H., editor

Published
2001
Full Text
View/download PDF

20. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee

Author

Trobaugh-Lotrario, Angela, primary, Katzenstein, Howard M., additional, Ranganathan, Sarangarajan, additional, Lopez-Terrada, Dolores, additional, Krailo, Mark D., additional, Piao, Jin, additional, Chung, Nadia, additional, Randazzo, Jessica, additional, Malogolowkin, Marcio H., additional, Furman, Wayne L., additional, McCarville, Elizabeth B., additional, Towbin, Alexander J., additional, Tiao, Greg M., additional, Dunn, Stephen P., additional, Langham, Max R., additional, McGahren, Eugene D., additional, Feusner, James, additional, Rodriguez-Galindo, Carlos, additional, Meyers, Rebecka L., additional, O'Neill, Allison F., additional, and Finegold, Milton J., additional

Published
2022
Full Text
View/download PDF

22. Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study

Author

Katzenstein, Howard M., primary, Malogolowkin, Marcio H., additional, Krailo, Mark D., additional, Piao, Jin, additional, Towbin, Alexander J., additional, McCarville, M. Beth, additional, Tiao, Gregory M., additional, Dunn, Stephen P., additional, Langham, Max R., additional, McGahren, Eugene D., additional, Finegold, Milton J., additional, Ranganathan, Sarangarajan, additional, Weldon, Christopher B., additional, Thompson, Patrick A., additional, Trobaugh‐Lotrario, Angela D., additional, O’Neill, Allison F., additional, Furman, Wayne L., additional, Chung, Nadia, additional, Randazzo, Jessica, additional, Rodriguez‐Galindo, Carlos, additional, and Meyers, Rebecka L., additional

Published
2021
Full Text
View/download PDF

27. Contributors

Author

Adams, Mark C., primary, Adibe, Obinna O., additional, Adler, Jeremy, additional, Adzick, N. Scott, additional, Albanese, Craig T., additional, Andrews, Walter S., additional, Applebaum, Harry, additional, Arca, Marjorie J., additional, Aronson, Daniel C., additional, Azizkhan, Richard G., additional, Baird, Robert, additional, Barnett, Sean, additional, Barnhart, Douglas C., additional, Barsness, Katherine A., additional, Bartlett, Robert H., additional, Baskin, Laurence S., additional, Beasley, Spencer W., additional, Bentz, Michael L., additional, Billmire, Deborah F., additional, Boulanger, Scott C., additional, Brandt, Mary L., additional, Brock, John W., additional, Brown, Rebeccah L., additional, Btaiche, Imad F., additional, Busuttil, Ronald W., additional, Caldamone, Anthony A., additional, Caniano, Donna A., additional, Caty, Michael G., additional, Chardot, Christophe, additional, Chung, Dai H., additional, Cilley, Robert E., additional, Colon, Nadja C., additional, Columbani, Paul M., additional, Coran, Arnold G., additional, Cotton, Robin T., additional, Cowles, Robert A., additional, Cox,, Charles S., additional, Dassinger, Melvin S., additional, Davidoff, Andrew M., additional, Davidson, Richard S., additional, Coppi, Paolo De, additional, Dicken, Bryan J., additional, Didelot, William, additional, DiFiore, John W., additional, Dillon, Patrick A., additional, Dillon, Peter W., additional, Donahoe, Patricia K., additional, Duchossois, Gina P., additional, Dunn, James C.Y., additional, Dutta, Sanjeev, additional, Eaton, Simon, additional, Ehrlich, Peter F., additional, Eichelberger, Martin R., additional, Elden, Lisa M., additional, Eliason, Jonathan L., additional, Emil, Sherif, additional, Escobar, Mauricio A., additional, Falcone,, Richard A., additional, Fallat, Mary E., additional, Farmer, Diana L., additional, Farmer, Douglas G., additional, Faro, Albert, additional, Fisher, Michael J., additional, Fishman, Steven J., additional, Fitzgerald, Tamara N., additional, Flake, Alan W., additional, Foglia, Robert P., additional, Ford, Henri R., additional, Franklin, Andrew, additional, Frischer, Jason S., additional, Fuller, Stephanie M.P., additional, Gandhi, Sanjiv K., additional, Garcia, Victor F., additional, Gatti, John M., additional, Gauderer, Michael W.L., additional, Geiger, James D., additional, Georgeson, Keith E., additional, Gingalewski, Cynthia A., additional, Glassberg, Kenneth I., additional, Glick, Philip L., additional, Gonzales, Kelly D., additional, Grikscheit, Tracy C., additional, Grosfeld, Jay L., additional, Groth, Travis W., additional, Gruessner, Angelika C., additional, Gruessner, Rainer W.G., additional, Gutierrez, Ivan M., additional, Guzzetta,, Philip C., additional, J. Hall, Jason, additional, Hamilton, Thomas E., additional, Harmon, Carroll M., additional, Harrison, Michael R., additional, Hayes-Jordan, Andrea, additional, Hays, Stephen R., additional, Healey, John H., additional, Hendren, W. Hardy, additional, Hering, Bernhard J., additional, Herndon, David N., additional, Hirose, Shinjiro, additional, Hirsch, Jennifer C., additional, Hirschl, Ronald B., additional, Hoganson, David M., additional, Holcomb, George W., additional, Höllwarth, Michael E., additional, Horn, B. David, additional, Huddleston, Charles B., additional, Hutchinson, Raymond J., additional, Hutson, John M., additional, Hyun, Grace, additional, Inge, Thomas H., additional, Jaksic, Tom, additional, Jea, Andrew, additional, Kaefer, Martin, additional, Kang, Kuang Horng, additional, Karsanac, Christopher J., additional, Kayes, Kosmas, additional, Kelly, Robert E., additional, Kiely, Edward M., additional, Klein, Michael D., additional, Krasin, Matthew J., additional, Krummel, Thomas M., additional, Kulungowski, Ann M., additional, Laberge, Jean-Martin, additional, Landsman, Ira S., additional, Langer, Jacob C., additional, La Quaglia, Michael P., additional, Laufer, Marc R., additional, Lee, Hanmin, additional, Lelli, Joseph L., additional, Levitt, Marc A., additional, Liau, James Y., additional, Lillehei, Craig, additional, Lindahl, Harry, additional, Liu, Gigi Y., additional, Lorenz, H. Peter, additional, Luerssen, Thomas G., additional, Lukish, Jeffrey R., additional, Lund, Dennis P., additional, Magee, John C., additional, McGahren, Eugene D., additional, McLaughlin, Eamon J., additional, McQuiston, Leslie T., additional, Meyers, Rebecka L., additional, Millar, Alastair J.W., additional, Minevich, Eugene, additional, Miranda, Edward P., additional, Mitchell, Michael E., additional, Mollen, Kevin P., additional, Moss, R. Lawrence, additional, Mouriquand, Pierre, additional, Murase, Noriko, additional, Murphy, J. Patrick, additional, Murphy, Joseph T., additional, Nance, Michael L., additional, Nathan, Saminathan S., additional, Newman, Kurt D., additional, Numanoglu, Alp, additional, Nwomeh, Benedict C., additional, Ohye, Richard G., additional, Oldham, Keith T., additional, O'Neill, James A., additional, Pakarinen, Mikko P., additional, Panait, Nicoleta, additional, Pearl, Richard H., additional, Peña, Alberto, additional, Pieretti, Rafael V., additional, Pierro, Agostino, additional, Piper, Hannah G., additional, Potsic, William P., additional, Pryor, Howard I., additional, Puligandla, Pramod S., additional, Puri, Prem, additional, Qureshi, Faisal G., additional, Rescorla, Frederick J., additional, Révillon, Yann, additional, Reyes, Jorge, additional, Reynolds, Marleta, additional, Rhee, Audrey C., additional, Rich, Barrie S., additional, Ricketts, Richard R., additional, Rink, Richard C., additional, Rintala, Risto J., additional, Rocchini, Albert P., additional, Rodeberg, David A., additional, Sadove, A. Michael, additional, Saggi, Bob H., additional, Scherer, L.R., additional, Schmid, Daniel B., additional, Scholz, Stefan, additional, Schwartz, Marshall Z., additional, Shamberger, Robert C., additional, Shapiro, Nina L., additional, Sheldon, Curtis A., additional, Shochat, Stephen J., additional, Sidell, Douglas, additional, Skinner, Michael A., additional, Smith, Jodi L., additional, Smith, Samuel D., additional, Snyder, Charles L., additional, Speer, Allison L., additional, Spitz, Lewis, additional, Spray, Thomas L., additional, Stanley, James C., additional, Starzl, Thomas E., additional, Stehr, Wolfgang, additional, Stolar, Charles J.H., additional, Storm, Phillip B., additional, Stylianos, Steven, additional, Subramaniam, Ramnath, additional, Superina, Riccardo, additional, Sutherland, David E.R., additional, Sutton, Leslie N., additional, Sydorak, Roman, additional, Sylvester, Karl G., additional, Teitelbaum, Daniel H., additional, Tepas, Joseph J., additional, Thomas, John C., additional, Thompson, Dana Mara, additional, Tovar, Juan A., additional, Upperman, Jeffrey S., additional, Vacanti, Joseph P., additional, van Aalst, John A., additional, Vane, Dennis W., additional, Allmen, Daniel Von, additional, Walkovich, Kelly, additional, Walsh, Danielle S., additional, Warner, Brad W., additional, Weber, Thomas R., additional, Weldon, Christopher B., additional, Wesson, David E., additional, Wetmore, Ralph F., additional, Willging, J. Paul, additional, Wilson, Jay M., additional, Woo, Lynn L., additional, Woo, Russell K., additional, Yerkes, Elizabeth B., additional, Ziegler, Moritz M., additional, and Zimmermann, Arthur, additional

Published
2012
Full Text
View/download PDF

29. Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.

Author

Katzenstein, Howard M., Malogolowkin, Marcio H., Krailo, Mark D., Piao, Jin, Towbin, Alexander J., McCarville, M. Beth, Tiao, Gregory M., Dunn, Stephen P., Langham, Max R., McGahren, Eugene D., Finegold, Milton J., Ranganathan, Sarangarajan, Weldon, Christopher B., Thompson, Patrick A., Trobaugh‐Lotrario, Angela D., O'Neill, Allison F., Furman, Wayne L., Chung, Nadia, Randazzo, Jessica, and Rodriguez‐Galindo, Carlos

Subjects
CISPLATIN, VINCRISTINE, HYPOKALEMIA, FEBRILE neutropenia, DOXORUBICIN, CLINICAL trials, HEPATOBLASTOMA
Abstract

Background: The Children's Oncology Group (COG) adopted cisplatin, 5‐flourouracil, and vincristine (C5V) as standard therapy after the INT‐0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubicin. Subsequent experience demonstrated doxorubicin to be effective in patients with recurrent disease after C5V, and this suggested that it could be incorporated to intensify therapy for patients with advanced disease. Methods: In this nonrandomized, phase 3 COG trial, the primary aim was to explore the feasibility and toxicity of a novel therapeutic cisplatin, 5‐flourouracil, vincristine, and doxorubicin (C5VD) regimen with the addition of doxorubicin to C5V for patients considered to be at intermediate risk. Patients were eligible if they had unresectable, nonmetastatic disease. Patients with a complete resection at diagnosis and local pathologic evidence of small cell undifferentiated histology were also eligible for an assessment of feasibility. Results: One hundred two evaluable patients enrolled between September 14, 2009, and March 12, 2012. Delivery of C5VD was feasible and tolerable: the mean percentages of the target doses delivered were 96% (95% CI, 94%‐97%) for cisplatin, 96% (95% CI, 94%‐97%) for 5‐fluorouracil, 95% (95% CI, 93%‐97%) for doxorubicin, and 90% (95% CI, 87%‐93%) for vincristine. Toxicity was within expectations, with death as a first event in 1 patient. The most common adverse events were febrile neutropenia (n = 55 [54%]), infection (n = 48 [47%]), mucositis (n = 31 [30%]), hypokalemia (n = 39 [38%]), and elevated aspartate aminotransferase (n = 28 [27%]). The 5‐year event‐free and overall survival rates for the 93 patients who did not have complete resection at diagnosis were 88% (95% CI, 79%‐93%) and 95% (95% CI, 87%‐98%), respectively. Conclusions: The addition of doxorubicin to the previous standard regimen of C5V is feasible, tolerable, and efficacious, and this suggests that C5VD is a good regimen for future clinical trials. The addition of doxorubicin to the previous standard regimen of cisplatin, 5‐flourouracil, and vincristine is a feasible, tolerable, and efficacious novel treatment regimen (cisplatin, 5‐flourouracil, vincristine, and doxorubicin). This regimen is a reasonable option for future clinical trials, especially those including patients with unresectable disease at diagnosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Contributors

Author

Albanese, Craig T., primary, Alonso, Maria H., additional, Arca, Marjorie J., additional, Bax, Klaas (N) M.A., additional, Brandt, Mary L., additional, Browne, Allen F., additional, Cina, Robert A., additional, Cortes, Raul A., additional, Dutta, Sanjeev, additional, Geiger, James D., additional, Georgeson, Keith E., additional, Holcomb, George W., additional, Holterman, Mark J., additional, Inge, Thomas H., additional, Irish, Michael S., additional, Jasonni, Vincenzo, additional, Kelly, Robert E., additional, La Quaglia, Michael P., additional, Lee, Hanmin, additional, Levitt, Marc A., additional, Little, Danny C., additional, Lobe, Thom E., additional, Martinez-Ferro, Marcelo, additional, Mattioli, Girolamo, additional, McGahren, Eugene D., additional, Meehan, John J., additional, Moir, Christopher R., additional, Morowitz, Michael J., additional, Nuss, Donald, additional, Ostlie, Daniel J., additional, Peña, Alberto, additional, Peters, Craig A., additional, Pini Prato, Alessio, additional, Poddoubnyi, Igor V., additional, Rescorla, Frederick J., additional, Rodgers, Bradley M., additional, Rothenberg, Steven S., additional, Ryckman, Frederick C., additional, St. Peter, Shawn D., additional, Schier, Felix, additional, Tiao, Greg M., additional, Tirabassi, Michael V., additional, Valla, Jean-Stephane, additional, van der Zee, David C., additional, and Wulkan, Mark L., additional

Published
2008
Full Text
View/download PDF

35. Contributors

Author

Adams, Mark C., primary, Adzick, N. Scott, additional, Albanese, Craig T., additional, Alexander, Fred, additional, Altman, R. Peter, additional, Andrassy, Richard J., additional, Andrews, Walter S., additional, Applebaum, Harry, additional, Arca, Marjorie J., additional, Arensman, Robert M., additional, Atkinson, James B., additional, Azizkhan, Richard G., additional, Baban, Anwar, additional, Barnhart, Douglas C., additional, Bartlett, Robert H., additional, Baskin, Laurence S., additional, Beasley, Spencer W., additional, Bentz, Michael L., additional, Boston, Victor E., additional, Boulanger, Scott C., additional, Bove, Edward L., additional, Brandt, Mary L., additional, Brock, John W., additional, Brown, Rebeccah L., additional, Browne, Marybeth, additional, Buchmiller, Terry L., additional, Busuttil, Ronald W., additional, Caird, Michelle S., additional, Caldamone, Anthony A., additional, Campbell, Darrell A., additional, Caniano, Donna A., additional, Caty, Michael G., additional, Chung, Dai H., additional, Cilley, Robert E., additional, Colombani, Paul M., additional, Cooper, Joel D., additional, Coran, Arnold G., additional, Cotton, Robin T., additional, Dalsing, Michael C., additional, Daneman, Alan, additional, Davidoff, Andrew M., additional, Davidson, Richard S., additional, DeMarco, Romano T., additional, DeUgarte, Daniel A., additional, Devaney, Eric, additional, Didelot, William, additional, DiFiore, John W., additional, Dillon, Patrick A., additional, Dillon, Peter W., additional, Donahoe, Patricia K., additional, Dunn, James C.Y., additional, Eaton, Simon, additional, Eichelberger, Martin R., additional, Ein, Sigmund H., additional, Ells, Carolyn, additional, Eppley, Barry L., additional, Fallat, Mary E., additional, Farmer, Diana L., additional, Farmer, Douglas G., additional, Fishman, Steven J., additional, Flake, Alan W., additional, Foglia, Robert P., additional, Fonkalsrud, Eric W., additional, Ford, Henri R., additional, Fuller, Stephanie M.P., additional, Garcia, Victor F., additional, Gatti, John M., additional, Gauderer, Michael W.L., additional, Geiger, James D., additional, Georgeson, Keith E., additional, Gingalewski, Cynthia A., additional, Glassberg, Kenneth I., additional, Glick, Philip L., additional, Gordon, Sherilyn A., additional, Grikscheit, Tracy C., additional, Grosfeld, Jay L., additional, Gruessner, Angelika C., additional, Gruessner, Rainer W.G., additional, Guzzetta, Philip C., additional, Harmon, Carroll M., additional, Harrison, Michael R., additional, Hayes-Jordan, Andrea A., additional, Hays, Stephen R., additional, Healey, John H., additional, Hendren, W. Hardy, additional, Hering, Bernhard J., additional, Herndon, David N., additional, Hirschl, Ronald B., additional, Holcomb, George W., additional, Huddleston, Charles B., additional, Hutchinson, Raymond J., additional, Hutson, John M., additional, Inge, Thomas, additional, Jasonni, Vincenzo, additional, Jibri, Nishwan, additional, Joyner, Byron D., additional, Kaefer, Martin, additional, Kawamoto, Henry K., additional, Kay, Robert M., additional, Kayes, Kosmas, additional, Kayton, Mark L., additional, Kelly, Robert E., additional, Kim, Stephen S., additional, Klein, Michael D., additional, Klement, Giannoula, additional, Krasin, Matthew J., additional, Krummel, Thomas M., additional, Laberge, Jean-Martin, additional, Landsman, Ira S., additional, La Quaglia, Michael P., additional, Lau, Stanley T., additional, Lee, Steven L., additional, Lelli, Joseph L., additional, Levitt, Marc A., additional, Lindahl, Harry, additional, Lobe, Thom E., additional, Loder, Randall T., additional, Luerssen, Thomas G., additional, Lukish, Jeffrey R., additional, Lund, Dennis P., additional, Madonna, Mary Beth, additional, Magee, John C., additional, Martucciello, Giuseppe, additional, Mathes, Stephen J., additional, McGahren, Eugene D., additional, McQuiston, Leslie T., additional, Metcalfe, Peter, additional, Millar, Alastair J.W., additional, Minevich, Eugene, additional, Miranda, Edward P., additional, Mitchell, Michael E., additional, Miyano, Takeshi, additional, Mount, Delora, additional, Mouriquand, Pierre, additional, Murase, Noriko, additional, Murphy, J. Patrick, additional, Nathan, Saminathan S., additional, Newman, Kurt D., additional, Numanoglu, Alp, additional, Nuss, Donald, additional, Ohye, Richard, additional, Oldham, Keith T., additional, O'Neill, James A., additional, Ong, Evelyn, additional, Oppenheim, William L., additional, Othersen, H. Biemann, additional, Pakarinen, Mikki, additional, Pandurangi, Keshav, additional, Pearl, Richard H., additional, Peña, Alberto, additional, Pieretti, Rafael V., additional, Pierro, Agostino, additional, Potsic, William P., additional, Puligandla, Pramod S., additional, Puapong, Devin P., additional, Puri, Prem, additional, Randolph, Judson G., additional, Rescorla, Frederick J., additional, Reyes, Jorge, additional, Ricketts, Richard R., additional, Rink, Richard C., additional, Rintala, Risto J., additional, Rocchini, Albert P., additional, Rode, Heinz, additional, Rodgers, Bradley M., additional, Sadove, A. Michael, additional, Saggi, Bob H., additional, Sanford, Arthur P., additional, Scherer, L.R., additional, Schnitzer, Jay J., additional, Schwartz, Marshall Z., additional, Shamberger, Robert C., additional, Shapiro, Nina L., additional, Sheldon, Curtis A., additional, Shochat, Stephen J., additional, Skinner, Michael A., additional, Smith, C.D., additional, Smith, Jodi L., additional, Smith, Samuel D., additional, Snyder, Charles L., additional, Spitz, Lewis, additional, Spray, Thomas L., additional, Starzl, Thomas E., additional, Stolar, Charles J.H., additional, Storm, Phillip B., additional, Stylianos, Steven, additional, Su, Wendy T., additional, Superina, Riccardo, additional, Sutherland, David E.R., additional, Sutton, Leslie N., additional, Tagge, Edward P., additional, Teitelbaum, Daniel H., additional, Templeman, Claire L., additional, Tekant, Gonca Topuzlu, additional, Tepas, Joseph J., additional, Thomas, Patrick B., additional, Thompson, Dana Mara, additional, Tovar, Juan A., additional, Upperman, Jeffrey S., additional, Vacanti, Joseph P., additional, Vane, Dennis W., additional, Vustar, Mirjana, additional, Warner, Brad W., additional, Weber, Thomas R., additional, Wesson, David E., additional, West, Karen W., additional, Wetmore, Ralph F., additional, Wiener, Eugene, additional, Wilson, Jay M., additional, Woo, Russell K., additional, Wu, Hsi-Yang, additional, Yerkes, Elizabeth, additional, Young, Daniel G., additional, and Ziegler, Moritz M., additional

Published
2006
Full Text
View/download PDF

36. Capillaries and arterioles are electrically coupled in hamster cheek pouch

Author

Beach, James M., McGahren, Eugene D., and Duling, Brian R.

Subjects
Hamsters as laboratory animals -- Research, Membrane potentials -- Physiological aspects, Microcirculation -- Physiological aspects, Blood circulation -- Physiological aspects, Capillaries -- Physiological aspects, Cardiology -- Research, Biological sciences
Abstract

An experiment was conducted on hamsters to demonstrate that electrical continuity between arteriolar and capillary levels of the microcirculation can be measured in situ. Data suggest the possibility that membrane potential changes integrated over capillary networks in response to the local environment may influence blood flow by spreading to arterioles. A direct demonstration of arteriolar vasomotor response along with conducted membrane potential changes in response to capillary stimulation would further test this hypothesis.

Published
1998

37. Capillaries demonstrate changes in membrane potential in response to pharmacological stimuli

Author

McGahren, Eugene D., Beach, James M., and Duling, Brian R.

Subjects
Capillaries -- Physiological aspects, Membrane potentials -- Physiological aspects, Endothelium -- Cytology, Biological sciences
Abstract

Research was conducted to test whether capillaries can detect changes in tissue metabolites and produce signals that are communicated upstream to resistance vessels. Capillary endothelial cells were evaluated for their capacity to respond to pharmacological stimuli while drugs were applied topically to short capillary segments by pressure ejection using a picospritzer. Results suggested that endothelial cells may posses alpha-1-receptors.

Published
1998

38. A test of the role of flow-dependent dilation in arteriolar responses to occlusion

Author

McGahren, Eugene D., Dora, Kim A., Damon, David N., and Duling, Brian R.

Subjects
Microcirculation -- Physiological aspects, Hemodynamics -- Physiological aspects, Blood flow -- Measurement, Erythrocytes -- Physiological aspects, Arterial occlusions -- Physiological aspects, Biological sciences
Abstract

The role of flow-dependent dilation in the regulation of the microvasculature was analyzed by measuring the diameter, red blood cell (RBC) velocity and flow or shear stress in hamster arterioles. Analysis of the microcirculatory beds of hamster and rat cremaster muscle after arteriolar occlusion indicated the absence of a causal relationship between changes in shear stress and feed vessel diameter. Furthermore, elevation of RBC velocity and shear stress was preceded by an increase in vessel diameter in hamster and rat cremaster muscle after arteriolar occlusion.

Published
1997

39. Ratiometric measurements of endothelial depolarization in arterioles with a potential-sensitive dye

Author

Beach, James M., McGahren, Eugene D., Xia, Jun, and Duling, Brian R.

Subjects
Methodology -- Research, Endothelium -- Physiological aspects, Arteries -- Analysis, Polarization (Electricity) -- Physiological aspects, Biological sciences
Abstract

A fluorescence ratio technique based on the dye 1-(3-sulfonatopropyl)-8-(beta-(2-(di-n-butylamino)-6-naphthyl)vinyl)pyridini um betaine (di-8-ANEPPS) aids accurate recording of membrane potential changes during vascular responses of arterioles. The membrane depolarization of intact arteriole endothelium of hamsters leads to a shift of the dye spectrum toward blue wavelengths. In isolated nonperfused arterioles, the ratio of fluorescent intensities corresponds with membrane potential during vasoconstriction. There is rapid depolarization and slow repolarization after potassium stimulation in the membrane.

Published
1996

45. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.

Author

O'Neill, Allison F., Towbin, Alexander J., Krailo, Mark D., Xia, Caihong, Gao, Yun, McCarville, M. Beth, Meyers, Rebecka L., McGahren, Eugene D., Tiao, Greg M., Dunn, Stephen P., Langham, Max R., Weldon, Christopher B., Finegold, Milton J., Ranganathan, Sarangarajan, Furman, Wayne L., Malogolowkin, Marcio, Rodriguez-Galindo, Carlos, Katzenstein, Howard M., O'Neill, Allison F., Towbin, Alexander J., Krailo, Mark D., Xia, Caihong, Gao, Yun, McCarville, M. Beth, Meyers, Rebecka L., McGahren, Eugene D., Tiao, Greg M., Dunn, Stephen P., Langham, Max R., Weldon, Christopher B., Finegold, Milton J., Ranganathan, Sarangarajan, Furman, Wayne L., Malogolowkin, Marcio, Rodriguez-Galindo, Carlos, and Katzenstein, Howard M.

Abstract

Purpose To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB) correlates with outcome. Methods Thirty-two patients with metastatic HB were enrolled on Children's Oncology Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and at the conclusion of therapy. All computed tomography scans and pathology reports were centrally reviewed, and information was collected regarding lung nodule number, size, laterality, timing of resolution, and pulmonary surgery. Results Among the 29 evaluable patients, only 31% met Response Evaluation Criteria in Solid Tumors (RECIST) for measurable metastatic disease. The presence of measurable disease by RECIST, the sum of nodule diameters greater than or equal to the cumulative cohort median size, bilateral disease, and ≥ 10 nodules were each associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065, P = .03, respectively), with nodule number meeting statistical significance. Ten patients underwent pulmonary resection/metastasectomy at various time points, the benefit of which could not be determined because of small patient numbers. Conclusion Children with metastatic HB have a poor prognosis. Overall tumor burden may be an important prognostic factor for these patients. Lesions that fail to meet RECIST size criteria (ie, those < 10 mm) at diagnosis may contain viable tumor, whereas residual lesions at the end of therapy may constitute eradicated tumor/scar tissue. Patients may benefit from risk stratification on the basis of the burden of lung metastatic disease at diagnosis.

Published
2017

46. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children’s Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children’s Oncology Group

Author

O’Neill, Allison F., primary, Towbin, Alexander J., additional, Krailo, Mark D., additional, Xia, Caihong, additional, Gao, Yun, additional, McCarville, M. Beth, additional, Meyers, Rebecka L., additional, McGahren, Eugene D., additional, Tiao, Greg M., additional, Dunn, Stephen P., additional, Langham, Max R., additional, Weldon, Christopher B., additional, Finegold, Milton J., additional, Ranganathan, Sarangarajan, additional, Furman, Wayne L., additional, Malogolowkin, Marcio, additional, Rodriguez-Galindo, Carlos, additional, and Katzenstein, Howard M., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results